Richard Colvin

Richard Colvin

Company: bluebird bio

Job title: Chief Medical Officer


Richard Colvin, MD, PhD, has served as Chief Medical Officer of bluebird since March 2021. Prior to bluebird, Rich was an executive director in translational medicine at Novartis. Rich completed his clinical and research fellowships in the Mass General Brigham Infectious Diseases Program, and completed his internship and residency at the Brigham and Women’s Hospital. Rich is on faculty at Harvard Medical School and sees patients in the Infectious Diseases clinic at MGH Chelsea. Rich received his MD and PhD from Duke University School of Medicine and his BS from Cornell University.


Monitoring Safety & Efficacy of Rare Gene Therapies During Clinical Development & in the Commercial Setting 11:15 am

Reviewing the potential direct and indirect risks of genetic therapies Implementing safety monitoring before and after approval of bluebird’s gene therapies Long-term follow-up of patients receiving genetic therapies now and in the futureRead more

day: Day 2 CLINICAL AM

Forward-Looking Landscaping & Impact on Clinical Trial Effectiveness 1:25 pm

Read more

day: Clinical - PM

Clinical Trial Design Nuances in Rare Diseases 10:55 am

Read more

day: Clinical - AM

Fireside Chat: So You Have an Accelerated Approval: What Now? 9:30 am

Outlining challenges in the post-market studies to provide confirmatory data of a clinical benefit Implications for drug developers if confirmatory trials are negative Exploring the challenge of these therapies being deemed “unproven” or “experimental” by private insurers Understanding how to operationalize and source data being requested by the FDARead more

day: Day One AM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.